Evidence map›Paper›PMID 40371133›Full record

ArticleAmerican journal of cancer research2025

Onvansertib inhibits cell proliferation and increases sensitivity to paclitaxel in uterine serous cancer cells.

Jennifer G Haag, Xiaochang Shen, Nikita Sinha, Shuning Chen, Boer Deng, Haomeng Zhang, Catherine John, Wenchuan Sun, Michael Emanuele, Chunxiao Zhou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Characterizing the Impact of the Cell Cycle on mRNA Lipid Nanoparticles.Journal of the American Chemical Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer G HaagDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Xiaochang ShenDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Nikita SinhaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Shuning ChenDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Boer DengDepartment of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital Beijing 100026, P. R. China.
Haomeng ZhangDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Catherine JohnDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Wenchuan SunDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Michael EmanueleDepartment of Pharmacology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Chunxiao ZhouDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.
Victoria Bae-JumpDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill Chapel Hill, NC 27599, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterine serous carcinoma (USC) belongs to the non-endometrioid subtype of endometrial cancer that is known for its highly aggressive behavior and poor prognosis, highlighting the warrant of novel strategies for the treatment of USC. PLK1 is a type of serine/threonine kinase that is crucial for controlling the progression of the cell cycle, DNA damage response, and genome stability. Targeting PLK1 exhibits potent anti-tumorigenic activity in pre-clinical models of multiple cancer types, and several PLK1 inhibitors have shown significant clinical benefit and favorable safety profiles alone or in combination with other chemotherapeutic agents. Onvansertib is an oral, selective PLK1 inhibitor that exhibits anti-proliferative activity in multiple types of cancer cell and animal models and has demonstrated clinical activity and a favorable safety profile in recent clinical trials. Hence, we investigated the anti-tumorigenic effects of onvansertib in USC cell lines. Nanomolar concentrations of onvansertib significantly inhibited cellular proliferation, led to cell cycle G2 arrest, induced cellular stress and apoptosis, caused DNA damage, and reduced cell adhesion and invasion in ARK-1 and SPEC-2 cells. The combination of onvansertib with paclitaxel demonstrated a synergistic effect in cell proliferation inhibition via inducing cell apoptosis and DNA damage. Our results provide preclinical evidence that onvansertib may be an effective strategy to treat USC and deserves further evaluation in animal models and clinical trials.

Indexed as

apoptosisOnvansertibpaclitaxelPLK1synergyuterine serous carcinoma

Identifiers

PMID40371133
PMCPMC12070104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.